Enhanced Anti-Cancer Therapy by Targeting the Pros1:Macrophage Mer Axis

Eric Ubil, PhD, MBA
Postdoctoral Fellow
Laboratory of H. S. Earp, III, MD
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

At the conclusion of this activity, the participant will be able to:

1. Categorize immune checkpoint targeted therapies
2. Describe what appears to be a widely used mechanism that tumors utilize to dampen the immune response
3. Demonstrate how a novel cell signaling pathway may be targeted to improve existing anti-cancer therapies

Accreditation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Credit Designation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships:
The following planners, moderators or speakers have the following financial relationship(s) with commercial interests to disclose: Nothing to disclose